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doi:10.1Objective: Bronchial stump dehiscence is still the most feared complication for the thoracic surgeon, with mor-
tality rates ranging from 25% to 75%. This study reports the histologic effect of adult stem cells in the healing
process of the bronchial stump after lung resection.
Methods:A left pneumonectomy was performed in 36 Wistar rats. Half of them received previously labeled bone
marrow-derived stem cells applied to the bronchial stump. In each group, 7 rats were sacrificed on day 7 and 11
rats were sacrificed on day 21. Macroscopic variables and histopathologic features were analyzed.
Results: On days 7 and 21, there were fewer adhesions in the stem cell group (P ¼ .042 and .031, respectively).
Bronchial stump restitutio ad integrum on day 21 was found predominantly in rats from the stem cell group
(P ¼ .012). At that time, the same group showed significantly less inflammation in every layer of the stump
(P< .050).
Conclusions: Bone marrow-derived stem cells administered topically on a bronchial stump are able to migrate,
reach the bronchial wall, and participate in the healing process. This induces fewer adhesions, less inflammatory
response, and better regeneration of the tissue. (J Thorac Cardiovasc Surg 2010;140:1397-401)E
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SIn recent years, countless studies dealing with the definition
and isolation of stem cells in various embryonic and adult
tissues have been performed. By definition, a stem cell is
an undifferentiated cell with asymmetric division capacity
that has the ability to give rise to another identical cell and
a precursor of a progeny committed to a more specialized
function, different from that of the tissue of origin.1 Embry-
onic stem cells are isolated from the embryo in the morula
phase or from the inner mass of the blastocyst, and they
can give rise to any cell line.2 Our study focuses on adult
stem cells derived from bone marrow stromal cells
(BMSCs). These are cells obtained from adult tissues or
the fetus before birth. Adult stem cells have been isolated
from the bone marrow, fat, intestine, skin, and liver, and sev-
eral studies have shown their ability to give rise to more spe-
cialized cell lines (ie, bowel, liver, pancreatic cells, skin,
muscle, bone, cartilage, and nervous system) when the
proper stimulus and environmental conditions occur.3,4
Both in vivo and ex vivo, there is evidence to support the
role of these cells in cicatrization and wound healing,
although the pathways to achieve this are still unknown.5
Bronchial dehiscence still remains one of the most feared
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The Journal of Thoracic and Carranging from 0.4% and 4% in the largest series and repre-
senting high rates of morbidity and mortality.6-8 Many
factors have been associated with its occurrence (right
pneumonectomy, chronic obstructive pulmonary disease,
radiation, and chronic and debilitating diseases).6,7,9
Extensive experimental and clinical work has been done to
develop a method for perfect closure of the bronchial
stump while preventing dehiscence (mechanical devices vs
manual suture, absorbable vs nonabsorbable material,
running vs interrupted suture), but none of these methods
have been shown to be superior to the others so far.
The current accepted practice among the community of
thoracic surgeons is to reinforce bronchial sutures with vas-
cularized tissue (ie, chest wall muscles, parietal pleura, azy-
gous vein, pericardial fat pad, omentum) in sutures at risk,
for example, after or before radiotherapy and bronchoplastic
procedures, or after a pneumonectomy.7
We postulate that BMSCs may play a role in improving
bronchial stump healing, thus preventing the occurrence of
bronchial stump dehiscence. Our study describes the influ-
ence of BMSCs in bronchial stump healing after a pneumo-
nectomy.MATERIALS AND METHODS
Isolation and Characterization of Bone Marrow
Stromal Cells
BMSCs were obtained from the large bones of 10 donor adult Wistar rats
(weighing 250 to 300 g) and expanded in vitro for 4 weeks. Bone marrow
was mechanically dissociated to obtain a homogeneous cell suspension
that was passed through 70-mm nylon mesh. For purification, this sample
was seeded on a Ficoll-Hypaque gradient (Beckman Coulter Inc, Fullerton,
Calif; density 1.077). The obtained cells were washed in Ca2þand Mg2þfree
Hanks’ balanced salt solution and placed in a 75-cm2 flask for tissue culture
with 12 mL alpha-minimum essential medium containing 20% fetal bovinediovascular Surgery c Volume 140, Number 6 1397
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Sserum, 2 mmol/L l-glutamine, 100 U/mL penicillin, 100 mg/mL streptomy-
cin, and 25 ng/mL amphotericin B. These cells were incubated at 37C in
5%CO2 for 3 days. At this time, nonadherent cells were removed by replac-
ing the medium. The culture medium was replaced 3 times per week. After
the primary cultures reached confluence, they were rinsed 3 times with
phosphate-buffered saline (PBS) and dissociated with 0.25% trypsin and
1 mmol/L EDTA for 5 minutes at 37C and subcultured at a density of
83 103 cells/cm2. BMSCs were identified by their mesenchymal morphol-
ogy and by cell surface expression of CD73, CD105, SH4, and vimentin,
being negative for CD34, CD45, CD3, CD14, CD19, CD38, glycophorin
A, and HLA II.10
Labeling
BMSCs were doubly labeled before transplantation. They were trans-
fected with a retrovirus (pRV-IRES CopGFP2i) expressing green fluores-
cent protein (GFP) supplied by Genetrix S.L. (Madrid, Spain). They were
also cultured with 1 mM 5-bromo-20-deoxyuridine (BrdU) (Sigma-Aldrich
S.A., Madrid, Spain) for 48 hours.
This allowed for detection of BMSCs both in fresh tissue samples (fluo-
rescent microscope) and immunohistochemical analysis (antibodies di-
rected against BrdU and GFP). At the time of infection, the culture
medium was replaced by 50 mL/cm2 of viral supernatant and 8 mg/mL of
polybrene. Subsequently, the samples were incubated for 6 hours at 37C,
and cells were allowed to grow in the standard medium for at least 48 hours
before analysis of the expression of the transgenic marker.
Animal Care and Anesthesia
A total of 36 female Wistar Hannover rats (Harlan Interfauna Iberica SL,
Barcelona, Spain), aged 3 months and weighing 200  20g (180–220 g),
were used in these experiments. Rats were housed in groups of 7 in Plexiglas
cages on wood chip bedding and maintained on a 12-hour light/12-hour
dark cycle (light on at 7 AM). Animals had free access to commercial rodent
food (CRM, Harlan Interfauna Iberica SL), and tap water was available ad
libitum from polyethylene water bottles. The environmental conditions
were constant: room temperature 20C to 21C and 50% to 60% relative
humidity. All animals were handled according to the guidelines of the
‘‘Guide for the Care and Use of Laboratory Animals’’ issued by the Amer-
ican National Society for Medical Research. The study was approved by the
institutional Animal Care and Use Committee of the Hospital Universitario
Puerta de Hierro.
For induction of anesthesia, each rat was placed in an induction chamber,
and a concentration of 5% isoflurane (Forane, Abbott Laboratories Ltd,
Kent, UK) vaporized in 100% oxygen at a flow rate of 8 L/min was added.
When animals had lost their palpebral reflex and jaw tone, tracheal intuba-
tion was performed using a 16-gauge polyethylene catheter (Abbott Ireland,
Sligo, Ireland). Correct placement of the catheter was confirmed by CO2
infrared-absorption analysis, and the catheter was then taped in place and
connected to a breathing machine (8050; Dra¨ger Medizintechnik GMBH,
Lubeck, Germany). We maintained an inspiratory time of 0.3 seconds, a re-
spiratory rate of 60 cycles per minute, an inspiratory pressure of 14 mbar,
and a fresh gas flow of 2 L/min of oxygen. The inspired concentration of
isoflurane was adjusted as necessary (2.1%–2.3%) on the basis of assess-
ment of the palpebral reflex and hemodynamic responses during instrumen-
tation. Rectal temperature was maintained between 37C and 38C by1398 The Journal of Thoracic and Cardiovascular Surmeans of a total temperature management system (Bair Huggers model
505; Augustine Medical Inc, Eden Prairie, Minn). A tail vein was catheter-
ized with a 24-gauge polyethylene catheter (Abbott Ireland) for the infusion
of morphine.
Surgery
Each animal underwent left pneumonectomy via a left posterolateral tho-
racotomy. Each structure of the hilum was individually ligated with a non-
absorbable 6-0 monofilament suture. Airway pressure was increased to the
maximum (70 mbar) under water seal to check for air leaks from the bron-
chial stump.
In each case, 0.4 mL of Tissucol (Baxter S.L., Valencia, Spain) diluted to
a thrombin concentration of 4 UI/mL was administered over the hilum. In
the study group, 3 million labeled BMSCs diluted in 100 mL of saline solu-
tion were injected under microscope visualization within the fibrin matrix in
close vicinity to the bronchial stump. The chest was then closed by layers
leaving a small bore drainage of 16F until the animal breathed by itself.
All procedures were performed by the same surgeon (D.G.A.).
Tissue Sampling
Seven animals in each group were euthanized after 7 days, and 11 ani-
mals per group were euthanized on day 21. All animals were anesthetized
and intubated again in the same manner. A re-thoracotomy was performed,
and the macroscopic appearance of the pleural space was recorded. The pa-
tency of the bronchial stump was tested by increasing airway pressure to
a maximum of 70 mbar, and animals were euthanized with an intracardiac
50 meq/kg potassium chloride injection (UCB Pharma, SA, Barcelona,
Spain). The 3 distal rings of the bronchial stump were resected en bloc. Sam-
ples were fixed for histologic study for 12 hours in 4% paraformaldehyde in
0.1 mol/L PBS, pH 7.4. After bronchial stump specimens were rinsed with
ice-cold 20% sucrose in PBS for 1 hour, they were incubated in 30% su-
crose and PBS overnight at 4C. The tissue was washed in PBS and embed-
ded in optimum cutting temperature medium (TAAB Lab, Aldermaston
Berks, UK) and cut in a cryostat at 5 mm. They were mounted on glass slides
for histologic study after hematoxylin-eosin staining.
For immunohistochemical studies, adjacent slides were placed in a boiled
citrate buffer (pH 6) in a microwave oven (650–720 W). After rinsing in
PBS, the sections were exposed to 3% H2O2 for 30 minutes to quench en-
dogenous peroxidase activity. Before incubation of primary antibodies, non-
specific binding was blocked for 1 hour with 3% normal serum from the
species in which the secondary antibody was raised, with 0.25% Triton
X-100 in PBS. The primary antibodies used were directed against anti-
BrdU monoclonal antibody (1:100; Chemicon International, Temecula,
Calif), anti-GFP (1:100; Serotec, Kidlington, UK), or anti Ki-67 (1:100;
Lab Vision Westinghouse Dr, Fremont, Calif). The sections were incubated
with secondary antibodies conjugated to biotin, 1:200 (Vector Inc, Burlin-
game, Calif). Subsequently, the sections incubated with secondary anti-
bodies conjugated to biotin were washed in PBS and incubated with
avidin-biotin-horseradish peroxidase complex (ABC reagent; Vector Inc).
30, 30-diaminobenzidine was used as a chromogen. Control slides lacking
primary or secondary antibodies were used. The sections were studied using
light and fluorescent microscopy.
Variables
All variables were measured on both days 7 and 21. We checked for the
presence of a bronchial fistula, and the rupture pressure of the stump was
tested at increasing airway pressures applied with the ventilator. Both mac-
roscopic and microscopic variables were reported, and marked stem cells
were sought in the histologic study.
The degree of adhesions was defined macroscopically as mild if they
could be dissected bluntly, moderate if they were located around the hi-
lum and some sharp dissection was needed, intense if they were extended
to the upper mediastinum, and very intense if the whole pleural space
was obliterated. In the microscopic stage, restitutio ad integrum wasgery c December 2010
TABLE 1. Day 7
Macroscopic Control (n ¼ 7) BMSC (n ¼ 7) P
Adhesions
No 1 (14.3%) 5 (71.4%) .042
Mild–moderate 4 (57.1%) 0
Intense–very intense 2 (28.6%) 2 (28.6%)
Bronchial stump
Normal 3 (42.9%) 6 (85.7%) NS
Capillaries 1 (14.3%) 1 (14.3%)
Abscesses 2 (28.6%) 0
Necrotic 1 (14.3%) 0
Microscopic
Restitutio ad integrum 0 0 NS
Mucosa
Severe inflammation 5 (71.4%) 5 (71.4%) NS
Diffuse fibrosis 0 0 NS
Diffuse ulceration 5 (71.4%) 6 (85.7%) NS
Infection 6 (85.7%) 5 (71.4%) NS
Neovascularization 6 (85.7%) 7 (100%) NS
Cartilage
Severe inflammation 4 (57.1%) 4 (57.1%) NS




7 (100%) 7 (100%) NS
Diffuse fibrosis 0 1 (14.3%) NS
Foreign body granuloma 7 (100%) 7 (100%) NS
Infection 6 (85.7%) 6 (85.7%) NS
Neovascularization 6 (85.7%) 6 (85.7%) NS
BMSC, Bone marrow-derived stem cell; NS, not significant.
FIGURE 1. BMSCs expressing GFP, some of them also co-expressing
proliferation marker Ki67 (white arrows) at day 7 (fluorescence and immu-
nohistochemical study with anti-Ki67 antibodies, 403).




Sdefined as a completely normal epithelium, submucosa, and cartilage
with neovascularization.
Statistical Design
This was an experimental, prospective, and randomized study. During
tissue harvest, the surgeon and pathologist were blinded to animal groups.
The Statistical Package for the Social Sciences 14.0 (SPSS Inc, Chicago,
Ill) was used for statistical analysis. We used a chi-square test for qualitative
variables, corrected chi-square for estimated frequencies less than 5, and the
Fisher exact test when required.
RESULTS
There were no signs of dehiscence at the time of re-
thoracotomy in any animal, not even when airway pressure
was increased to 70 mbar. Pleural secretions, when present,
were always serous.
Day 7
The macroscopic appearance at day 7 was similar in both
groups, except regarding the presence of adhesions, which
was less in the BMSC group (P¼ .042) (Table 1). Histologic
analysis did not show any difference on the seventh day.
There were no cases of restitutio ad integrum.
At this stage of the cicatrization process, light microscopy
study showed intense inflammation with diffuse ulceration
of the mucosa, intense neovascularization, and signs of in-
fection with foreign body granulomas in the peribronchial
pleura (Table 1).
We identified stem cells in the samples obtained, with
a mean of 5 cells per field (range, 1–6) showing the morpho-
logic features of fibroblasts, chondrocytes, and adipocytes.
Among them, 2.5% showed cell proliferation markers (Ki
67) (Figure 1).
Day 21
On day 21, macroscopic appearance was also similar be-
tween both groups, again with the exception of the presence
of adhesions, which was significantly less in the BMSC
group (P ¼ .031) (Table 2). The histologic examination at
this time showed a significant number of stumps in the
BMSC group with complete restoration of the normal archi-
tecture and morphology of the mucosa and bronchial wall
(Figure 2), as well as less inflammation in every layer com-
pared with the control group (Table 2). We observed the
same proportion of stem cells with mesenchymal morpho-
logic features as in the BMSC group on day 7 (Figure 3),
but with less expression of Ki 67 (1%).
DISCUSSION
The critical factor that led to these results is the lower level
of inflammation in the BMSC group. Inflammatory cells
play a pivotal role in wound healing. They assist in microbial
decontamination, produce multiple growth factors that pro-
mote the healing process, and help in the clearance of cellu-
lar death and tissue remodeling. Nevertheless, recent skinThe Journal of Thoracic and Carstudies have shown that inflammatory cells may not be
that effective in wound healing in a clean and aseptic
scenario, such as a surgical wound.11 In this environment,
inflammation may act as a negative factor, as several exper-
imental studies have shown. Martin and colleagues12diovascular Surgery c Volume 140, Number 6 1399
TABLE 2. Day 21
Macroscopic Control (n ¼ 11) BMSC (n ¼ 11) P
Adhesions
No 0 6 (54.5%) .031
Mild–moderate 6 (54.5%) 5 (45.5%)
Intense–very intense 5 (45.5%) 0
Bronchial stump
Normal 5 (45.5%) 5 (45.5%) .226
Capillaries 2 (18.2%) 3 (27.3%)
Abscesses 4 (37.3%) 3 (27.2%)
Microscopic
Restitutio ad integrum 1 (9.09%) 7 (63.6%) .012
Mucosa
Severe inflammation 6 (54.5%) 1 (9.1%) .014
Diffuse fibrosis 0 2 (18.2%) NS
Diffuse ulceration 4 (36.4%) 2 (18.2%) NS
Infection 5 (45.5%) 3 (27.3%) NS
Neovascularization 8 (72.7%) 10 (90.9%) NS
Cartilage
Severe inflammation 5 (45.5%) 1 (9.1%) .020




6 (54.5%) 2 (18.2%) .020
Diffuse fibrosis 1 (9.1%) 0 NS
Foreign body granuloma 2 (18.2%) 1 (9.1%) NS
Infection 6 (54.5%) 6 (54.5%) NS
Neovascularization 9 (81.8%) 6 (54.5%) NS
BMSC, Bone marrow-derived stem cells; NS, not significant.
FIGURE 3. BMSCs with morphologic features of chondrocytes at day 21
(immunohistochemical study with anti-BrdU antibodies, 403).




Srecently showed how PU.1 null rats (without macrophages
or neutrophils) healed without any inflammation or scar at
the wound site, whereas rats lacking the inhibitor of neutro-
phil protease secretion (an anti-inflammatory factor) had an
impaired wound healing process.13
Our results confirm this hypothesis. We observed signifi-
cantly less inflammation in every layer of the bronchialFIGURE 2. Bronchial stump at 21 days. Perfect restoration of the mucosa
and bronchial wall (hematoxylin-eosin 203).
1400 The Journal of Thoracic and Cardiovascular Surstump in the BMSC group. Moreover, in this group the
stump was completely restored, showing no signs of scar
formation, with the histologic features of an intact bronchial
epithelium and cartilage.
There is also experimental evidence that these cells reduce
collagen fiber accumulation in a model with bleomycin-
induced pulmonary fibrosis,14 reinforcing the idea that
stem cells may influence the healing process in terms of tis-
sue restitution without scar formation.
Notably, we also observed a significantly lower level of
adhesions in the BMSC group compared with the control
group. In a similar experimental study in colon anastomosis
using sutures with adult stem cells, Pascual and coworkers15
observed fewer adhesions during the first postoperative
week. This finding is the macroscopic correlation of the lim-
ited inflammatory activity shown under the light microscope.
Little is known about the pathophysiologic pathways un-
derlying these effects. Researchers postulate that BMSCs
have a low inherent immunogenicity and may play a role
in the mechanisms that control the immunologic response
to an injury, because in vivo they show the ability to inhibit
both the proliferation of T cells and secretion of proinflam-
matory cytokines.16
Another important issue that arises in the use of stem cells
is the method of administration and its vehicle. Shigemura
and colleagues17 showed that topical administration of au-
tologous adult stem cells in a polyglycolic acid matrix after
lung volume reduction surgery in rats resulted in better alve-
olar and vascular regeneration, as well as improved respira-
tory function, with an increase in oxygenation and exercise
capacity in those animals receiving stem cells. In another
experimental model, Wong and colleagues18 showed that
after naphthalene-induced lung injury, endotracheal admin-
istration of bone marrow-derived stem cells allowed for re-
generation of the respiratory epithelium, remaining with
proliferation capacity for at least 120 days.gery c December 2010
Gomez-de-Antonio et al Evolving Technology/Basic ScienceWe isolated viable stem cells during the first week after
topical administration using a fibrin-modified matrix (Tissu-
col). It is remarkable that the same proportion of viable stem
cells was seen at week 3. This can be explained because the
matrix may act as a reservoir for viable stem cells that can




One of the major limitations of this study is that although
the matrix has been shown to be an acceptable biomaterial (it
is adherent for cells, allows for migration, and finally de-
grades), it contains human and bovine proteins, which surely
enhanced the inflammatory activity in the recipient rat. The
reason for using this solution was that its clinical use in tho-
racic surgery is common. We do believe, however, that a bet-
ter ratio of viable cells with less of an inflammatory response
can be obtained using different matrices. We are currently us-
ing autologous platelet-enriched plasma with encouraging
results.
Another limitation is that the minimum amount of cells
needed to achieve clinical results is unknown. We have used
3 million BMSCs in 100 mL of saline because that is the max-
imum concentration of cells that can be efficiently injected
through a needle 0.4 mm in diameter. The mediastinal pleura
after a pneumonectomy is a hostile environment for cells to
graft because it is not completely sterile and is in constant
movement, so we wanted to have the highest concentration
of stem cells around the bronchial stump. It would be interest-
ing to design a dose-response study to determine the adequate
concentration of BMSCs needed to obtain good results.
One important recent controversy is the ability of BMSCs
to give rise to cells of a different lineage, known as cellular
transdifferentiation. There have been in vivo and in vitro re-
ports supporting this capability,3,4,19-21 whereas others
suggest that those findings may represent cellular fusions
with resident cells or even genetic changes that adult stem
cells acquire during in vitro processing.22-25 We have not
observed any BMSCs with the morphologic features of
epithelial cells in the samples analyzed, and we believe
this is a crucial point in determining whether BMSCs can
be used to obtain functional lung tissue. We hope that
further studies will help shed light on this issue.CONCLUSIONS
Topical administration of rat bone marrow-derived stem
cells in the conditions of our experiment improves the heal-
ing process of the bronchial stump, leading to fewer adhe-
sions, less inflammation, and complete histologic restoration.
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